Messenger Ribo Nucleic Acid (mRNA) Vaccine Contract Development And Manufacturing Organization (CDMO) Market Report 2026

Messenger Ribo Nucleic Acid (mRNA) Vaccine Contract Development And Manufacturing Organization (CDMO) Market Overview

• Messenger Ribo Nucleic Acid (mRNA) Vaccine Contract Development And Manufacturing Organization (CDMO) market size has reached to $8.41 billion in 2025 • Expected to grow to $17.1 billion in 2030 at a compound annual growth rate (CAGR) of 15.3% • Growth Driver: Rising Prevalence Of Infectious And Emerging Diseases Fueling The Growth Of The Market Due To Increasing Global Disease Outbreaks And Rapid Vaccine Response Requirements • Market Trend: GMP-Like mRNA Manufacturing Services Accelerating Early-Stage Development • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Messenger Ribo Nucleic Acid (mRNA) Vaccine Contract Development And Manufacturing Organization (CDMO) Market?

Messenger ribonucleic acid (mRNA) vaccine contract development and manufacturing organization (CDMO) refers to contract development and manufacturing organizations that provide outsourced services for the development, scale-up, and commercial manufacturing of messenger ribonucleic acid-based Vaccines. These organizations support activities such as process development, formulation, analytical testing, fill-finish operations, and regulatory compliance, enabling vaccine developers to accelerate production while reducing infrastructure investment and operational complexity. The main service types of messenger ribo nucleic acid (mRNA) vaccine contract development and manufacturing organizations (CDMOs) include process development, manufacturing, analytical and quality control, fill finish, packaging, and other service types. Process development refers to services that optimize and establish scalable mRNA vaccine production processes for clinical and commercial use. These services are applied to vaccine types such as COVID-19 vaccines, cancer vaccines, infectious disease vaccines, and other vaccine types. The scales of operation include preclinical, clinical, and commercial, and the end users are pharmaceutical companies, biotechnology companies, research institutes, and other end users.

What Is The Messenger Ribo Nucleic Acid (mRNA) Vaccine Contract Development And Manufacturing Organization (CDMO) Market Growth Forecast?

The messenger ribo nucleic acid (mrna) vaccine contract development and manufacturing organization (cdmo) market size is expected to see rapid growth in the next few years. It will grow to $17.1 billion in 2030 at a compound annual growth rate (CAGR) of 15.3%. The growth in the forecast period can be attributed to expansion of mrna cancer vaccines, growth in personalized vaccines, higher cdmo partnerships, demand for rapid scale manufacturing, increased pipeline of mrna therapies. Major trends in the forecast period include lipid nanoparticle formulation services, rapid mrna process scale up, integrated fill finish outsourcing, modular vaccine manufacturing suites, end to end mrna development services.

Global Messenger Ribo Nucleic Acid (mRNA) Vaccine Contract Development And Manufacturing Organization (CDMO) Market Segmentation

1) By Service Type: Process Development; Manufacturing; Analytical And Quality Control; Fill Finish; Packaging; Other Service Types 2) By Vaccine Type: COVID-19 Vaccines; Cancer Vaccines; Infectious Disease Vaccines; Other Vaccine Types 3) By Scale of Operation: Preclinical; Clinical; Commercial 4) By End-User: Pharmaceutical Companies; Biotechnology Companies; Research Institutes; Other End-Users Subsegments: 1) By Process Development: Formulation Optimization; Cell Line Development; Upstream Process Development; Process Scale-Up 2) By Manufacturing: Lipid Nanoparticle Production; Enzymatic Capping; Purification Process 3) By Analytical And Quality Control: Potency Testing; Purity Analysis; Stability Testing; Identity Testing; Microbial Testing 4) By Fill Finish: Aseptic Filling; Vial Filling; Syringe Filling; Lyophilization 5) By Packaging: Primary Packaging; Secondary Packaging; Labeling Operations; Cold Chain Packaging; Unit Dose Packaging 6) By Other Service Types: Regulatory Support Services; Technology Transfer Services; Contract Development Services; Consulting Services; Supply Chain Management

What Is The Driver Of The Messenger Ribo Nucleic Acid (mRNA) Vaccine Contract Development And Manufacturing Organization (CDMO) Market?

The rising prevalence of infectious and emerging diseases is expected to propel the growth of the mRNA vaccine CDMO market going forward. Infectious and emerging diseases are illnesses caused by pathogenic microorganisms that spread rapidly or newly arise due to factors such as environmental change, urbanization, and increased global connectivity. Growing international travel, population density, and interconnected supply chains have accelerated pathogen transmission, making disease outbreaks more frequent, widespread, and difficult to contain. mRNA vaccine CDMOs play a critical role in addressing these challenges by enabling the rapid development, scalable manufacturing, and flexible production of vaccines needed to respond to evolving infectious threats. mRNA technologies require specialized manufacturing infrastructure and technical expertise, prompting vaccine developers to rely on contract development and manufacturing organizations to accelerate timelines and ensure production readiness during outbreaks. For instance, in May 2024, according to the World Health Organization (WHO), a Switzerland-based United Nations' specialized agency for global health, as of 30 April 2024, more than 7.6 million dengue cases were reported globally to WHO, including 3.4 million confirmed cases, over 16,000 severe cases, and more than 3,000 deaths. The increase has been particularly pronounced in the Region of the Americas, where cases exceeded seven million by April 2024, surpassing the 2023 annual total of 4.6 million cases. Therefore, the rising prevalence of infectious and emerging diseases is driving the growth of the mRNA vaccine CDMO market.

Key Players In The Global Messenger Ribo Nucleic Acid (mRNA) Vaccine Contract Development And Manufacturing Organization (CDMO) Market

Major companies operating in the messenger ribo nucleic acid (mrna) vaccine contract development and manufacturing organization (cdmo) market are Sanofi S.A., Thermo Fisher Scientific Inc., FUJIFILM Diosynth Biotechnologies U.S.A. Inc., Danaher Corporation, Boehringer Ingelheim BioXcellence GmbH & Co. KG, AGC Biologics A/S, Eurofins Scientific SE, Lonza Group AG, BioNTech SE, Samsung Biologics Co. Ltd., WuXi Biologics (Cayman) Inc., Siegfried Holding AG, Recipharm AB, Vetter Pharma International GmbH, CordenPharma GmbH & Co. KG, Ajinomoto Bio-Pharma Services Inc., Novasep Holding S.A.S., Rentschler Biopharma SE, IDT Biologika GmbH, Wacker Biotech GmbH

Global Messenger Ribo Nucleic Acid (mRNA) Vaccine Contract Development And Manufacturing Organization (CDMO) Market Trends and Insights

Major companies operating in the mRNA vaccine CDMO market are increasingly focusing on advanced innovations such as phase-appropriate GMP mRNA contract development and manufacturing services to accelerate preclinical and IND-enabling development while maintaining regulatory-aligned quality standards and shorter timelines. Phase-appropriate GMP-like mRNA manufacturing refers to a production approach designed to deliver high-quality, regulatory-aware mRNA material suitable for preclinical and early development stages, without the cost and operational complexity associated with full GMP manufacturing. For instance, in May 2025, GenScript Biotech Corporation, a China-based global biotechnology reagents and services provider, launched a GMP-like mRNA manufacturing service aimed at supporting preclinical and IND-enabling development. The service delivers high-quality, regulatory-aware mRNA with reduced lead times and lower costs compared to traditional full GMP manufacturing, reflecting the growing demand for flexible, phase-appropriate CDMO solutions in the mRNA vaccine market.

What Are Latest Mergers And Acquisitions In The Messenger Ribo Nucleic Acid (mRNA) Vaccine Contract Development And Manufacturing Organization (CDMO) Market?

In September 2024, Areterna LLC, a US-based biotech company, partnered with Biomay AG to enhance global access to high-quality, cost-effective mRNA vaccine CDMO solutions. Through this partnership, Aeterna and Bio may aim to jointly expand end-to-end mRNA CDMO services across Europe and North America by combining GMP manufacturing capabilities with advanced mRNA design, formulation, and raw material expertise. Biomay AG is an Austria-based contract development and manufacturing organization specialized in mRNA vaccine CDMO, including GMP manufacturing of mRNA, plasmid DNA, and recombinant proteins for clinical and commercial applications.

Regional Insights

North America was the largest region in the mRNA vaccine contract development and manufacturing organization (CDMO) market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Messenger Ribo Nucleic Acid (mRNA) Vaccine Contract Development And Manufacturing Organization (CDMO) Market?

The messenger ribonucleic acid (mRNA) vaccine contract development and manufacturing organization (CDMO) market includes revenues earned by entities through process development services, cell-free transcription optimization, plasmid DNA production services, messenger ribonucleic acid synthesis services, formulation development services, lipid nanoparticle formulation services, and analytical testing services. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Messenger Ribo Nucleic Acid (mRNA) Vaccine Contract Development And Manufacturing Organization (CDMO) Market Report 2026?

The messenger ribo nucleic acid (mrna) vaccine contract development and manufacturing organization (cdmo) market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the messenger ribo nucleic acid (mrna) vaccine contract development and manufacturing organization (cdmo) industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.